Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.
Grövdal M, Nahi H, Gahrton G, Liwing J, Waage A, Abildgaard N, Pedersen PT, Hammerstrøm J, Laaksonen A, Bazia P, Terava V, Ollikainen H, Silvennoinen R, Putkonen M, Anttila P, Porkka K, Remes K. Grövdal M, et al. Among authors: porkka k. Bone Marrow Transplant. 2015 Jun;50(6):808-12. doi: 10.1038/bmt.2015.39. Epub 2015 Apr 13. Bone Marrow Transplant. 2015. PMID: 25867654 Clinical Trial.
[The wild development of hematology].
Remes K, Porkka K. Remes K, et al. Among authors: porkka k. Duodecim. 1998;114(12):1161, 1163. Duodecim. 1998. PMID: 11524760 Finnish. No abstract available.
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, Räsänen A, Vapaatalo M, Remes K, Lundán T, Hjorth-Hansen H, Vakkila J, Simonsson B, Mustjoki S, Porkka K. Koskenvesa P, et al. Among authors: porkka k. Eur J Haematol. 2014;92(5):413-20. doi: 10.1111/ejh.12258. Epub 2014 Jan 28. Eur J Haematol. 2014. PMID: 24372965
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
Kontro M, Kumar A, Majumder MM, Eldfors S, Parsons A, Pemovska T, Saarela J, Yadav B, Malani D, Fløisand Y, Höglund M, Remes K, Gjertsen BT, Kallioniemi O, Wennerberg K, Heckman CA, Porkka K. Kontro M, et al. Among authors: porkka k. Leukemia. 2017 Feb;31(2):301-309. doi: 10.1038/leu.2016.222. Epub 2016 Aug 8. Leukemia. 2017. PMID: 27499136
Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.
Majumder MM, Silvennoinen R, Anttila P, Tamborero D, Eldfors S, Yadav B, Karjalainen R, Kuusanmäki H, Lievonen J, Parsons A, Suvela M, Jantunen E, Porkka K, Heckman CA. Majumder MM, et al. Among authors: porkka k. Oncotarget. 2017 May 5;8(34):56338-56350. doi: 10.18632/oncotarget.17630. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915594 Free PMC article.
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.
Kolonen A, Sinisalo M, Huhtala H, Rimpiläinen J, Rintala H, Sankelo M, Koivunen E, Silvennoinen R, Räty R, Ruutu T, Volin L, Porkka K, Jantunen E, Nousiainen T, Kuittinen T, Penttilä K, Pyörälä M, Säily M, Koistinen P, Kauppila M, Itälä-Remes M, Ollikainen H, Rauhala A, Kairisto V, Pelliniemi TT, Elonen E; Finnish Leukemia Group. Kolonen A, et al. Among authors: porkka k. Eur J Haematol. 2022 Sep;109(3):257-270. doi: 10.1111/ejh.13805. Epub 2022 Jun 14. Eur J Haematol. 2022. PMID: 35634931 Clinical Trial.
Interferon alpha for treatment of chronic myeloid leukemia.
Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K. Simonsson B, et al. Among authors: porkka k. Curr Drug Targets. 2011 Mar 1;12(3):420-8. doi: 10.2174/138945011794815301. Curr Drug Targets. 2011. PMID: 21143150 Review.
226 results